Novo Nordisk’s Share Recovery Picks Up as Legal, Pipeline, and Pill Catalysts Converge

Novo Nordisk’s stock has clawed back more than a third of its losses since the March 2026 trough, closing at €41.56 on Tuesday after a 9% weekly surge. The shares were last seen changing hands around €41.24, a level that puts them just above a critical technical marker: the 200-day moving average, which analysts have pegged in a narrow band between €41.00 and €41.05. The Relative Strength Index has climbed to the 67–69 range, signalling that the rally is entering overbought territory, but the underlying drivers — a string of company-specific wins — have given investors fresh conviction.

A South African court ruling delivered on Monday dealt a blow to counterfeit competition. The High Court in Pretoria ordered iDexis to cease all production and promotion of products containing semaglutide, the active ingredient in Novo’s blockbusters Ozempic and Wegovy. The decision marks the latest salvo in the Danish pharma group’s expanding legal campaign; it has already filed more than 130 lawsuits across 40 US states and is now training its sights on international markets.

Separately, the company secured a major regulatory green light in Britain. On 11 June, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved an oral formulation of Wegovy — the first weight-loss GLP-1 pill to be authorised in the country. The oral version has already exceeded internal expectations: first-quarter 2026 revenue reached roughly 2.3 billion Danish kroner, nearly double what the company had forecast. The UK approval opens a new international growth channel for a product that is already supply-constrained.

Yet the market’s gaze is firmly fixed on the US Food and Drug Administration’s verdict on CagriSema, expected by the end of this year. The dual GLP-1 and amylin analogue is Novo’s next big bet in obesity and type 2 diabetes. The REDEFINE-1 study showed a mean weight loss of 22.7%, slightly below the company’s own 25% threshold and trailing Eli Lilly’s Zepbound. What could tip the scales in Novo’s favour is the breadth of the data package: the REIMAGINE-1 and REIMAGINE-2 trials, simultaneously published in The Lancet Diabetes & Endocrinology and presented at the ADA 2026 congress, demonstrated meaningful improvements in both HbA1c and body weight in patients with type 2 diabetes. A dual label for obesity and diabetes would dramatically expand CagriSema’s addressable patient population and help justify premium pricing.

Meanwhile, the Novo Nordisk Foundation has kicked off a pan-European research push dubbed CardioMetabolic Bridge. The initiative will receive €60 million over six years, with the first laboratory opening in London this month and additional sites in Germany and Italy to follow. The goal is to accelerate the development of new therapies for obesity, diabetes and cardiovascular disease — a reminder that the pipeline extends well beyond CagriSema. Zenagamtide, a next-generation GLP-1/amylin receptor agonist under investigation in both oral and subcutaneous formulations, could extend the company’s obesity franchise deep into the next decade.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The share buyback programme, launched in February 2026 and running until February 2027 with a ceiling of 15 billion Danish kroner, is providing a technical floor. So far it has helped absorb selling pressure as the stock climbed off its March lows.

But the bullish narrative has to contend with a sobering reality. Novo Nordisk’s full-year 2026 guidance calls for a contraction of 4% to 12% in constant-currency revenue and operating profit — the first top-line decline in years. US pricing headwinds are intensifying: lower realised prices, reduced Medicaid reimbursements, and a most-favoured-nation clause are compressing margins. Patent expirations on semaglutide in certain international markets add structural drag that no single approval can fully offset. Eli Lilly and an emerging swarm of biosimilar makers have already eroded Novo’s market share.

Technically, the stock remains stretched. At €41.24 it is only 0.6% above the 200-day average — a level that has historically acted as resistance during sustained downturns. The 52-week high of €61.20 still stands about 33% above the current price. A pullback to the 100-day moving average near €36.48 would not be unusual if the rally loses steam.

The next near-term trigger will be Novo’s upcoming quarterly results, which will show whether the revenue decline lands near the top or bottom of the forecast range. A slowdown closer to 4% would bolster the recovery thesis. But the definitive event remains the FDA’s decision on CagriSema. A clean approval with a dual label for obesity and type 2 diabetes could propel the stock sustainably above the 200-day line. Any setback, from a narrow label to requests for additional data, would refocus attention on the structural earnings headwinds. Until then, the combination of a Pretoria court victory, a UK pill approval, and a hefty buyback programme has given Novo Nordisk’s shares a much-needed floor — but not yet a ceiling.